OTCMKTS:EMMA Emmaus Life Sciences (EMMA) Stock Price, News & Analysis → Trump is sounding the alarm (From Preserve Gold) (Ad) Free EMMA Stock Alerts $0.10 0.00 (0.00%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$0.10▼$0.1050-Day Range$0.09▼$0.1352-Week Range$0.05▼$0.34Volume1 shsAverage Volume4,059 shsMarket Capitalization$6.19 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort Interest Get Emmaus Life Sciences alerts: Email Address Ad Preserve GoldTrump is sounding the alarmEurope is one of the latest to release a central bank digital currency and along with it, new cash rules. Christine Lagarde, President of the European Central Bank, shared "Now we have in Europe this threshold, above 1,000 euros you cannot pay cash… if you get caught you are fined or you are going to jail". Are you prepared?Click here to get your complimentary retirement guide! About Emmaus Life Sciences Stock (OTCMKTS:EMMA)Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. The company was founded in 2000 and is headquartered in Torrance, California.Read More EMMA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EMMA Stock News HeadlinesApril 17, 2024 | msn.comDistrict 11 wrestling: Kinney, Fanelli, Smith earn Scholar-Athlete awardsApril 15, 2024 | finance.yahoo.comEmmaus Life Sciences Reports Delayed Filing of Annual ReportApril 26, 2024 | Preserve Gold (Ad)Trump is sounding the alarmEurope is one of the latest to release a central bank digital currency and along with it, new cash rules. Christine Lagarde, President of the European Central Bank, shared "Now we have in Europe this threshold, above 1,000 euros you cannot pay cash… if you get caught you are fined or you are going to jail". Are you prepared?April 10, 2024 | chicago.suntimes.comThe Museum of Science and Industry closed for mysterious reasons last week. Here’s whyApril 10, 2024 | investing.comEmmaus Life Sciences Inc (EMMA)April 4, 2024 | msn.comPeabody Museum Review: Smearing ScienceMarch 27, 2024 | wsj.comEmmaus Life Sciences Inc.February 24, 2024 | msn.comHomeless charity seeks volunteers to help with eBay operationsApril 26, 2024 | Preserve Gold (Ad)Trump is sounding the alarmEurope is one of the latest to release a central bank digital currency and along with it, new cash rules. Christine Lagarde, President of the European Central Bank, shared "Now we have in Europe this threshold, above 1,000 euros you cannot pay cash… if you get caught you are fined or you are going to jail". Are you prepared?February 23, 2024 | msn.comDiscovery World named one of the best science museums in USA Today's 10Best Readers' Choice AwardsFebruary 22, 2024 | msn.comTexas Tech University Health Sciences Center announces Simulation Program reaccreditationFebruary 18, 2024 | abcnews.go.comSaving democracy is central to Biden's campaign. Will it resonate with voters?February 2, 2024 | finance.yahoo.comEmmaus Life Sciences Receives Marketing Authorization for Puerto RicoFebruary 1, 2024 | msn.comScience Museum of Western Virginia announces grand opening of ‘The Eye’January 18, 2024 | msn.comEmmaus wrestlers roll their way over “flat” FreedomJanuary 17, 2024 | news.yahoo.comTransgender row at Science Museum over claims reworked exhibit is 'even more insidious'January 12, 2024 | msn.comBiden says Austin still has his confidence, but not revealing hospitalization was lapse in judgmentJanuary 8, 2024 | msn.comDenver Museum of Nature & Science gets makeover with East Wing renovation projectJanuary 4, 2024 | sfgate.comA local guide to science museums near San FranciscoJanuary 4, 2024 | msn.comScience Museum of Minnesota receives largest gift in organization's historyNovember 17, 2023 | msn.comThe Museum of Illusions in Philadelphia meets science with immersive funNovember 14, 2023 | cbsnews.comNew exhibit at the Academy of Natural Sciences takes you back millions of years into historyNovember 14, 2023 | finanznachrichten.deEmmaus Life Sciences, Inc.: Emmaus Life Sciences Reports Q3 2023 Financial ResultsNovember 14, 2023 | msn.comEmmaus Life Sciences GAAP EPS of -$0.01, revenue of $5MNovember 14, 2023 | finance.yahoo.comEmmaus Life Sciences Reports Q3 2023 Financial ResultsNovember 10, 2023 | msn.comSeattle nonprofit wants to help all students love math, using school programs and in-person exhibitsNovember 10, 2023 | msn.comBest Museums for Kids in Philly: Children’s Museums and Family-Friendly MuseumsSee More Headlines Receive EMMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Emmaus Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:EMMA CUSIPN/A CIK822370 Webwww.emmausmedical.com Phone(310) 214-0065Fax866-294-2611Employees54Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-10,620,000.00 Net Margins-16.66% Pretax Margin-16.42% Return on EquityN/A Return on Assets-9.73% Debt Debt-to-Equity RatioN/A Current Ratio0.15 Quick Ratio0.12 Sales & Book Value Annual Sales$18.39 million Price / Sales0.34 Cash FlowN/A Price / Cash FlowN/A Book Value($0.69) per share Price / Book-0.14Miscellaneous Outstanding Shares61,850,000Free Float40,200,000Market Cap$6.19 million OptionableNot Optionable Beta1.61 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Willis C. Lee M.S. (Age 64)Co-President, COO & Chairman of the Board Comp: $240kMr. Yasushi Nagasaki CPA (Age 57)CPA, Chief Financial Officer Comp: $250kMr. George Sekulich (Age 58)Co-President, Chief Commercial Officer & Director Mr. Dale E. Short J.D.Legal Consultant & Corporate SecretaryDr. Charles W. Stark Pharm.D (Age 69)Pharm.D., Senior Vice President of Medical Affairs, Clinical, Regulatory Mr. Kurt H. Kruger M.B.A. (Age 69)M.S., Consultant Comp: $300.02kMore ExecutivesKey CompetitorsAyala PharmaceuticalsNASDAQ:ADXSHoth TherapeuticsNASDAQ:HOTHSonnet BioTherapeuticsNASDAQ:SONNXenetic BiosciencesNASDAQ:XBIOAvenue TherapeuticsNASDAQ:ATXIView All Competitors EMMA Stock Analysis - Frequently Asked Questions How have EMMA shares performed in 2024? Emmaus Life Sciences' stock was trading at $0.1001 at the beginning of 2024. Since then, EMMA shares have decreased by 0.1% and is now trading at $0.10. View the best growth stocks for 2024 here. Are investors shorting Emmaus Life Sciences? Emmaus Life Sciences saw a drop in short interest in the month of April. As of April 15th, there was short interest totaling 700 shares, a drop of 12.5% from the March 31st total of 800 shares. Based on an average trading volume of 800 shares, the days-to-cover ratio is presently 0.9 days. View Emmaus Life Sciences' Short Interest. How do I buy shares of Emmaus Life Sciences? Shares of EMMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:EMMA) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTrump is sounding the alarmPreserve GoldBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Emmaus Life Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
